ArticleDrug and alcohol dependence2020
Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State.
Article in Drug and alcohol dependence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- A Novel Care Navigation Intervention for Patients with Methamphetamine Use Disorder.Community mental health journal · 2026Trial
- Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.Drug and alcohol dependence · 2022Trial
- Interest in contingency management and reducing stimulant use among syringe service program participants.Journal of substance use and addiction treatment · 2025Article
- Prescribed medications for patients with amphetamine-type stimulant use disorder seen in rural-serving Pacific Northwest primary care clinics.Addiction science & clinical practice · 2025Article
- Expanding Access to Medications for Opioid Use Disorder: Federal Policy Is Only a Part of the Solution.American journal of public health · 2024Article
- Substance use patterns, sociodemographics, and health profiles of harm reduction service recipients in Burlington, Vermont.Harm reduction journal · 2024Article
- Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes.Substance abuse and rehabilitation · 2024Article
- A qualitative study of people who use methamphetamine during the early COVID-19 pandemic to inform future ED harm reduction strategies.International journal of emergency medicine · 2023Article
- "That Line Just Kept Moving": Motivations and Experiences of People Who Use Methamphetamine.The western journal of emergency medicine · 2023Article
- The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.Addiction science & clinical practice · 2022Article
- Characterizing stimulant overdose: A qualitative study on perceptions and experiences of "overamping".The International journal on drug policy · 2022Article
- Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction.Annals of the New York Academy of Sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMethamphetamine use is increasing, and opioid use remains elevated in the US. Understanding interest in reducing/stopping substance use among people who inject drugs (PWID), as well as types of help wanted, can inform interventions.
methodsData from the 2019 Washington State Syringe Exchange Survey were used in logistic regression analyses to assess if demographics, substance use, and concern about anxiety or depression were associated with interest in reducing/stopping substance use among people whose main drug was methamphetamine or opioids. Types of help wanted to reduce/stop use are reported.
resultsOf 583 participants included, 76 % reported opioids were their main drug, of whom 82 % were interested in reducing/stopping their opioid use. 24 % reported methamphetamine as their main drug, of whom 46 % were interested in reducing/stopping their methamphetamine use. Among those whose main drug was an opioid, female gender (AOR:2.19, p = .023) and concern about depression (AOR:3.04, p = .002) were associated with interest in reducing/stopping opioid use. Among participants whose main drug was methamphetamine, being in jail in the past year and having an infection likely related to injection (e.g., abscess) in the past year were associated with over twice the odds of interest in reducing/stopping methamphetamine use (AOR:2.14, p = .056 and 2.43, p = .052, respectively); however, these findings were not significant. Several types of help to reduce/stop use were endorsed.
conclusionThere were high, though differing, levels of interest in reducing/stopping opioid or methamphetamine use and in a range of support services. PWID should be asked about interest in reducing/stopping use and provided appropriate support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.